OPK vs PRGO vs HLN vs PAHC

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus -14. 9% for OPKO Health, Inc. (OPK). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate OPKO Health, Inc. (OPK) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haleon plc (HLN) is the cheapest at 19.

0x versus Phibro Animal Health Corporation at 36. 3x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Phibro Animal Health Corporation wins at 1. 90x versus Haleon plc's 2. 63x — a reasonable growth-adjusted valuation.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to -70. 5% for OPKO Health, Inc. (OPK). Over 10 years, the gap is even starker: PAHC returned +128. 6% versus OPK's -89. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Haleon plc (HLN) is the lower-risk stock at 0.

06β versus Phibro Animal Health Corporation's 1. 38β — meaning PAHC is approximately 2157% more volatile than HLN relative to the S&P 500. On balance sheet safety, OPKO Health, Inc. (OPK) carries a lower debt/equity ratio of 34% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus -14. 9% for OPKO Health, Inc. (OPK). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, PAHC leads at 11. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Haleon plc (HLN) is the more profitable company, earning 15.

1% net margin versus -37. 2% for OPKO Health, Inc. — meaning it keeps 15. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HLN leads at 22. 4% versus -36. 1% for OPK. At the gross margin level — before operating expenses — HLN leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Phibro Animal Health Corporation (PAHC) is the more undervalued stock at a PEG of 1. 90x versus Haleon plc's 2. 63x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OPK: 156. 2% to $2. 87.

In this comparison, PRGO (9.

8% yield), HLN (1. 9% yield), PAHC (1. 1% yield) pay a dividend. OPK does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Haleon plc (HLN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 1. 9% yield). Both have compounded well over 10 years (HLN: +31. 7%, OPK: -89. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OPK is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; HLN is a mid-cap quality compounder stock; PAHC is a small-cap high-growth stock. PRGO, HLN, PAHC pay a dividend while OPK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.